-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Head-To-Head Analysis: Better Therapeutics (BTTX) Vs. Its Competitors
Head-To-Head Analysis: Better Therapeutics (BTTX) Vs. Its Competitors
Better Therapeutics (NASDAQ:BTTX – Get Rating) is one of 33 publicly-traded companies in the "Health services" industry, but how does it compare to its rivals? We will compare Better Therapeutics to similar companies based on the strength of its analyst recommendations, institutional ownership, dividends, valuation, earnings, profitability and risk.
Insider & Institutional Ownership
7.5% of Better Therapeutics shares are held by institutional investors. Comparatively, 48.6% of shares of all "Health services" companies are held by institutional investors. 59.4% of Better Therapeutics shares are held by company insiders. Comparatively, 21.6% of shares of all "Health services" companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Get Better Therapeutics alerts:Risk & Volatility
Better Therapeutics has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500. Comparatively, Better Therapeutics' rivals have a beta of 1.19, meaning that their average stock price is 19% more volatile than the S&P 500.
Profitability
This table compares Better Therapeutics and its rivals' net margins, return on equity and return on assets.| Net Margins | Return on Equity | Return on Assets | |
| Better Therapeutics | N/A | -200.73% | -114.68% |
| Better Therapeutics Competitors | -325.87% | -676.77% | -37.31% |
Analyst Recommendations
This is a summary of recent recommendations for Better Therapeutics and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Better Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| Better Therapeutics Competitors | 7 | 131 | 277 | 0 | 2.65 |
Better Therapeutics presently has a consensus target price of $14.00, indicating a potential upside of 858.90%. As a group, "Health services" companies have a potential upside of 97.82%. Given Better Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Better Therapeutics is more favorable than its rivals.
Earnings and Valuation
This table compares Better Therapeutics and its rivals gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Better Therapeutics | $10,000.00 | -$40.33 million | -0.72 |
| Better Therapeutics Competitors | $1.36 billion | -$98.47 million | 29.07 |
Better Therapeutics' rivals have higher revenue, but lower earnings than Better Therapeutics. Better Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Summary
Better Therapeutics beats its rivals on 8 of the 11 factors compared.
About Better Therapeutics
(Get Rating)
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. Its clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
Receive News & Ratings for Better Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Better Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Better Therapeutics (NASDAQ:BTTX – Get Rating) is one of 33 publicly-traded companies in the "Health services" industry, but how does it compare to its rivals? We will compare Better Therapeutics to similar companies based on the strength of its analyst recommendations, institutional ownership, dividends, valuation, earnings, profitability and risk.
Better Treateutics(纳斯达克代码：BTTX-GET Rating)是“健康服务”行业的33家上市公司之一，但与其竞争对手相比如何？我们将根据分析师的建议、机构所有权、股息、估值、收益、盈利能力和风险将Better Treateutics与类似公司进行比较。
Insider & Institutional Ownership
内部人与机构所有权
7.5% of Better Therapeutics shares are held by institutional investors. Comparatively, 48.6% of shares of all "Health services" companies are held by institutional investors. 59.4% of Better Therapeutics shares are held by company insiders. Comparatively, 21.6% of shares of all "Health services" companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Better Treateutics 7.5%的股份由机构投资者持有。相比之下，所有“健康服务”公司48.6%的股份由机构投资者持有。Better Treateutics 59.4%的股份由公司内部人士持有。相比之下，所有“健康服务”公司21.6%的股份由公司内部人士持有。强大的机构持股表明，捐赠基金、对冲基金和大型基金管理公司相信，一只股票有望实现长期增长。
Risk & Volatility
风险与波动性
Better Therapeutics has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500. Comparatively, Better Therapeutics' rivals have a beta of 1.19, meaning that their average stock price is 19% more volatile than the S&P 500.
Better Treateutics的贝塔系数为1.36，这意味着其股价的波动性比标准普尔500指数高36%。相比之下，Better Treateutics的竞争对手的贝塔系数为1.19，这意味着它们的平均股价波动性比标准普尔500指数高19%。
Profitability
盈利能力
| Net Margins | Return on Equity | Return on Assets | |
| Better Therapeutics | N/A | -200.73% | -114.68% |
| Better Therapeutics Competitors | -325.87% | -676.77% | -37.31% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 更好的治疗学 | 不适用 | -200.73% | -114.68% |
| Better Treateutics的竞争对手 | -325.87% | -676.77% | -37.31% |
Analyst Recommendations
分析师建议
This is a summary of recent recommendations for Better Therapeutics and its rivals, as reported by MarketBeat.com.
据MarketBeat.com报道，这是对Better Treeutics及其竞争对手最近建议的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Better Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| Better Therapeutics Competitors | 7 | 131 | 277 | 0 | 2.65 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 更好的治疗学 | 0 | 0 | 2 | 0 | 3.00 |
| Better Treateutics的竞争对手 | 7 | 131 | 277 | 0 | 2.65 |
Better Therapeutics presently has a consensus target price of $14.00, indicating a potential upside of 858.90%. As a group, "Health services" companies have a potential upside of 97.82%. Given Better Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Better Therapeutics is more favorable than its rivals.
Better Treateutics公司目前的共识目标价为14美元，这表明潜在的上涨幅度为858.90%。作为一个整体，“健康服务”公司有97.82%的潜在上行空间。鉴于Better Treeutics更高的共识评级和更高的可能上行空间，股票研究分析师显然认为Better Treateutics比其竞争对手更有利。
Earnings and Valuation
收益和估值
This table compares Better Therapeutics and its rivals gross revenue, earnings per share and valuation.
这张表格比较了Better Treeutics及其竞争对手的毛收入、每股收益和估值。
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Better Therapeutics | $10,000.00 | -$40.33 million | -0.72 |
| Better Therapeutics Competitors | $1.36 billion | -$98.47 million | 29.07 |
| 总收入 | 净收入 | 市盈率 | |
| 更好的治疗学 | $10,000.00 | -4,033万元 | -0.72 |
| Better Treateutics的竞争对手 | 13.6亿美元 | -9,847万元 | 29.07 |
Better Therapeutics' rivals have higher revenue, but lower earnings than Better Therapeutics. Better Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Better Treateutics的竞争对手比Better Treeutics的收入更高，但收益更低。Better Treateutics的市盈率低于竞争对手，这表明它目前比行业内的其他公司更负担得起。
Summary
摘要
Better Therapeutics beats its rivals on 8 of the 11 factors compared.
Better Treateutics在比较的11个因素中有8个击败了竞争对手。
About Better Therapeutics
关于Better Treatetics
(Get Rating)
(获取评级)
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. Its clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
Better Treateutics，Inc.，一家处方数字治疗公司，开发了一种认知行为疗法，以解决心脏代谢性疾病的原因。该公司开发基于软件的处方数字疗法平台，用于治疗糖尿病、心脏病和其他心脏代谢疾病。其临床开发候选药物旨在治疗心脏代谢性疾病，包括2型糖尿病、高血压、高脂血症、非酒精性脂肪性肝病、非酒精性脂肪性肝炎和慢性肾脏疾病。该公司的主要候选产品是BT-001，这是一种治疗2型糖尿病的研究PDT平台。Better Treateutics，Inc.成立于2015年，总部位于加利福尼亚州旧金山。
Receive News & Ratings for Better Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Better Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每天收到更好的治疗新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯，接收最新新闻和分析师对Better Treateutics和相关公司的评级的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧